Multiple Myeloma
Conditions
Keywords
Drug Therapy
Brief summary
The purpose of this study is to determine the effect of ixazomib maintenance therapy on progression free survival (PFS) compared with placebo, in participants with NDMM who have had a major response (complete response \[CR\], very good partial response \[VGPR\], or partial response \[PR\]) to initial therapy and who have not undergone SCT.
Detailed description
The drug being tested in this study is called ixazomib citrate. Ixazomib citrate is being tested to slow progressive disease (PD) and improve overall survival in people who have NDMM who have had a major positive response to initial therapy and have not undergone SCT. This study will look at the effect of ixazomib citrate has on the length of time that participants are free of PD and their overall survival. The study will enrol approximately 700 participants. Participants will be randomly assigned (by chance, like flipping a coin) in 3:2 ratio to Ixazomib or matching placebo groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need): * Ixazomib citrate initiates at 3 mg which will be escalated to 4 mg with cycle 5 day 1 * Placebo (dummy inactive pill) - this is a capsule that looks like the study drug but has no active ingredient All participants will be asked to take one capsule on Days 1, 8 and 15 of each 28-day cycle. The treatment period will be approximately 24 months (equivalent to 26 cycles) or until patients experience PD or unacceptable toxicities, whichever occurs first. This multi-center trial will be conducted worldwide. The overall time to participate in this study is approximately 78 to 106 months. Participants will make 28 visits to the clinic during the treatment period and will continue to make follow-up visits every 4 weeks until the next line of therapy begins. Participants will also be contacted by telephone every 12 weeks after last treatment visit for a follow-up assessment.
Interventions
DRUGPlacebo
Ixazomib placebo-matching capsules.
DRUGIxazomib
Ixazomib capsules.
Sponsors
Takeda
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult male or female participants 18 years or older with a confirmed diagnosis of symptomatic newly diagnosed multiple myeloma (NDMM) according to standard criteria. 2. Completed 6 to 12 months (± 2 weeks) of initial therapy, during which the participant was treated to best response, defined as the best response maintained for 2 cycles after the M-protein nadir is reached. 3. Documented major response (PR, VGPR, CR) according to the International Myeloma Working Group (IMWG) uniform response criteria, version 2011, after this initial therapy. 4. Female participants who: * Are postmenopausal for at least 1 year before the screening visit, OR * Are surgically sterile, OR * If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 90 days after the last dose of study drug, OR * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence \[eg, calendar, ovulation, symptothermal, postovulation methods\] and withdrawal are not acceptable methods of contraception.) Male participants, even if surgically sterilized (that is, status postvasectomy), who: * Agree to practice effective barrier contraception during the entire study Treatment period and through 90 days after the last dose of study drug, OR * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence \[example, calendar, ovulation, symptothermal, postovulation methods for the female partner\] and withdrawal are not acceptable methods of contraception.) 5. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care. 6. Complete documentation of the details of the initial therapy before randomization including cytogenetics and International Staging System (ISS) is available. 7. Eastern Cooperative Oncology Group Performance Status of 0 to 2. 8. Suitable venous access for the study-required blood sampling and consent for the specific amounts that will be taken. 9. Is willing and able to adhere to the study visit schedule and other protocol requirements including blood sampling and bone marrow aspiration. 10. Must meet the following clinical laboratory criteria at study entry: * Absolute neutrophil count (ANC) greater than or equal to (≥) 1,000 per cubic millimeter (/mm\^3) without growth factor support and platelet count ≥75,000/mm\^3. Platelet transfusions to help participants meet eligibility criteria are not allowed within 3 days before randomization. * Total bilirubin less than or equal to (≤) 1.5\*the upper limit of the normal range (ULN). * Alanine aminotransferase and aspartate aminotransferase ≤ 3\*ULN. * Calculated creatinine clearance ≥ 30 milliliter per minute (mL/min) (using the Cockcroft-Gault equation).
Exclusion criteria
1. Multiple myeloma that has relapsed after, or was not responsive to, initial therapy. 2. Prior SCT. 3. Radiotherapy within 14 days before randomization. 4. Diagnosed or treated for another malignancy within 5 years before randomization or previous diagnosis with another malignancy. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection. 5. Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period. 6. Major surgery within 14 days before randomization. 7. Central nervous system involvement. 8. Infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before randomization. 9. Diagnosis of Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS), plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome. 10. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, uncontrolled congestive heart failure, unstable angina, or myocardial infarction within the past 6 months. 11. Systemic treatment with strong cytochrome P450 3A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or St. John's wort within 14 days before randomization. 12. Ongoing or active infection, known human immunodeficiency virus (HIV) positive, active hepatitis B or C infection. 13. Comorbid systemic illnesses or other severe concurrent disease that, in the judgment of the investigator, would make the participant inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens (example, PN that is Grade 1 with pain or Grade 2 or higher of any cause). 14. Psychiatric illness or social situation that would limit compliance with study requirements. 15. Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent. 16. Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment. 17. Treatment with any investigational products within 30 days before randomization.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | From randomization until PD or death (up to 52 months) | PFS is defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause, as evaluated by an independent review committee (IRC) according to International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurs first. Per IMWG criteria, PD is defined as, increase of 25% of lowest response value in one or more of following criteria: serum M-component (absolute increase ≥0.5 g/ deciliter (dL)); or urine M-component (absolute increase ≥200 mg/24-hour); difference between involved and uninvolved free light chains (FLC) levels (absolute increase \>10 mg/dL); or bone marrow plasma cell percentage (absolute plasma cell percentage ≥10%); development of new/ increase in size of existing bone lesions or soft tissue plasmacytoma; or development of hypercalcemia (corrected serum calcium \>11.5mg/dL). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Achieve or Maintain Any Best Response Category During the Treatment Period | Up to 27 months | Response was assessed according to IMWG criteria based on IRC assessment. Best response included PR, VGPR and CR. PR= \>=50% reduction of serum M protein and \>=90% or \<200 mg reduction urinary M protein in 24-hour, or \>50% decrease in difference between involved and uninvolved FLC levels, or \>50% reduction in bone marrow plasma cells, if bone marrow plasma cells \>30% and \>50% reduction in size of soft tissue plasmacytomas at baseline. VGPR= \>90% reduction (\<100 mg/24-hour) in serum M-protein + urine M-protein detectable by immunofixation but not on electrophoresis. Complete response= \>5% plasma cells in myelogram with absence of paraprotein in serum and urine according to immunofixation. |
| Time to Progression (TTP) | From randomization until PD or death (up to 52 months) | TTP is defined as the time from the date of randomization to the date of first documentation of PD, using IMWG criteria. |
| Progression Free Survival 2 (PFS2) | From the date of randomization to every 12 weeks until second PD or death (up to 88 months) | PFS2 is defined as the time from the date of randomization to objective PD on next-line treatment using IMWG criteria, or death due to any cause, whichever occurred first. |
| Time to Next Line Therapy (TTNT) | From randomization until PD or death (up to 52 months) | TTNT is defined as the time from the date of randomization to the date of the first dose of next-line antineoplastic therapy. |
| Time to End of the Next-line of Therapy After Study Treatment | From randomization until PD or death (up to 52 months) | Time to end of the next line of therapy is defined as the time from the date of randomization to the date of last dose of the next line of antineoplastic therapy following study treatment. |
| Duration of Next-line Therapy | From randomization until PD or death (up to 52 months) | Duration of next-line therapy is defined as the time from the date of the first dose of the next line of antineoplastic therapy coming after study treatment to the date of the last dose. |
| Percentage of Participants Who Develop a New Primary Malignancy | From randomization until PD or death (up to 52 months) | — |
| Percentage of Participants With Conversion From Minimal Residual Disease (MRD) Positive to MRD Negative | Up to 52 months | Bone marrow aspirates and blood samples were sent to a central laboratory and were assessed for MRD using flow cytometry. MRD negativity was defined as absence of MRD and MRD positivity was defined as presence of MRD. MRD was assessed by 8-color flow cytometry with the IMWG recommended sensitivity of 10\^-5. |
| Correlation of MRD Status With PFS and OS | From randomization up to 52 months | PFS is defined as the time from the date of randomization to the date of first documentation of PD or death from any cause, as evaluated by an IRC according to IMWG criteria, or death due to any cause, whichever occurred first, assessed for up to 52 months in this outcome measure. OS was measured as the time from the date of randomization to the date of death, assessed for up to 52 months in this outcome measure. Participants with various types of known MRD status were pooled together for analysis of overall survival in this outcome measure. |
| Overall Survival (OS) | From the date of randomization and every 12 weeks after PD on next-line therapy until death (up to 88 months) | OS was measured as the time from the date of randomization to the date of death. |
| PFS in a High-risk Population | From randomization until PD or death (up to 52 months) | High-risk population included but not be limited to participants carrying del17, t(4;14), t(14;16). PFS was defined as the time from the date of randomization to the date of first documentation of PD or death from any cause. |
| Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26, progression free survival follow-up (PFSFU)- Visit 37 and progressive disease follow-up (PDFU)- Visit 26 (cycle length=28 days) | ECOG performance status assesses a participant's performance status on a 6-point scale ranging from 0=fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (\>50% of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited self-care, confined to bed/chair \>50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5=dead. Lower grades indicate improvement. |
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | First dose of study drug through 30 days after last dose of study drug (up to 88 months) | An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAEs were defined as events that occurred after administration of the first dose of ixazomib or placebo through 30 days after the last dose of ixazomib or placebo. A SAE means any untoward medical occurrence that resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was considered medically significant. |
| Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Baseline, Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26 (cycle length=28 days) | The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The change from baseline in GHS (EORTC QLQ-C30) score is presented. Participant responses to the question How would you rate your overall health during the past week? are scored on a 7-point scale (1=very poor to 7=excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall GHS. |
| Correlation Between Frailty Status and PFS and OS | From randomization up to 52 months | Participant's frailty status is classified as fit, unfit or frail on the bases of 4 components: age, the Charlson comorbidity scoring system without age weighting, the Katz index of independence in activities of daily living, and the Lawton instrumental activities of daily living scale. The sum of the 4 frailty scores equals the total frailty score. A total frailty score of 0 corresponds to a frailty status of fit; a total score of 1, to unfit; and a total score of 2 or more, to frail. PFS is defined as the time from the date of randomization to the date of first documentation of PD or death from any cause, as evaluated by an IRC according to IMWG criteria, or death due to any cause, whichever occurs first, assessed for up to 52 months in this outcome measure. OS will be measured as the time from the date of randomization to the date of death, assessed for up to 52 months in this outcome measure. |
| Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 1 (1 and 4 hours post-dose Day 1, Days 8 and 15 pre-dose); Cycle 2 and 5 (Days 1 and 8 pre-dose) and Cycles 3, 4, 6 to 10 (Day 1 pre-dose) (cycle length=28 days) | Plasma concentrations of the complete hydrolysis product of ixazomib citrate (ixazomib) were measured using a validated liquid chromatography-tandem mass spectrometry (LC/MS/MS) assay. |
| Time to Resolution of Peripheral Neuropathy (PN) Events | Up to 52 months | PN is defined as the event in the high-level term of peripheral neuropathies not elsewhere classified (NEC) according to the medical dictionary for regulatory activities (MedDRA). A PN event was considered as resolved if its final outcome was resolved with no subsequent PN event of the same preferred term occurring on the resolution date or the day before and after. Time to resolution was defined as the time from the initial onset date (inclusive) to the resolution date for resolved events. |
| Time to Improvement of PN Events | Up to 52 months | PN is defined as the event in the high-level term of peripheral neuropathies NEC according to the MedDRA. A PN event was considered as resolved if its final outcome was resolved with no subsequent PN event of the same preferred term occurring on the improvement date or the day before and after. Time to improvement was defined as the time from the initial onset date (inclusive) to the improvement of event. |
| OS in a High-risk Population | From the date of randomization and every 12 weeks after PD on next-line therapy until death (up to 88 months) | High-risk population included but not be limited to participants carrying cytogenetic deletion (del)17, translocation \[t\](4;14), t(14;16). OS was measured as the time from the date of randomization to the date of death. |
Countries
Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Mexico, Poland, Portugal, Russia, Serbia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, United States
Participant flow
Recruitment details
Participants took part in the study from 09 April 2015 to 26 August 2022.
Pre-assignment details
Participants with newly diagnosed multiple myeloma not treated with stem cell transplantation (SCT) were enrolled and randomized in a 3:2 ratio to receive ixazomib or placebo respectively.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Ixazomib placebo-matching capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 through 26. | 281 |
| Ixazomib Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 to 4 that may have been escalated to 4 mg thereafter up to Cycle 26. | 425 |
| Total | 706 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 115 | 181 |
| Overall Study | Lost to Follow-up | 8 | 8 |
| Overall Study | Missing | 2 | 1 |
| Overall Study | Reason not Specified | 107 | 159 |
| Overall Study | Withdrawal by Patient | 49 | 76 |
Baseline characteristics
| Characteristic | Ixazomib | Total | Placebo |
|---|---|---|---|
| Age, Continuous | 72.3 years STANDARD_DEVIATION 6.87 | 72.5 years STANDARD_DEVIATION 6.83 | 72.8 years STANDARD_DEVIATION 6.77 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 46 Participants | 82 Participants | 36 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 366 Participants | 603 Participants | 237 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 13 Participants | 21 Participants | 8 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 63 Participants | 102 Participants | 39 Participants |
| Race (NIH/OMB) Black or African American | 15 Participants | 20 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 15 Participants | 24 Participants | 9 Participants |
| Race (NIH/OMB) White | 330 Participants | 557 Participants | 227 Participants |
| Region of Enrollment Argentina | 2 Participants | 4 Participants | 2 Participants |
| Region of Enrollment Australia | 9 Participants | 20 Participants | 11 Participants |
| Region of Enrollment Austria | 3 Participants | 5 Participants | 2 Participants |
| Region of Enrollment Belgium | 1 Participants | 1 Participants | 0 Participants |
| Region of Enrollment Brazil | 27 Participants | 43 Participants | 16 Participants |
| Region of Enrollment Canada | 3 Participants | 7 Participants | 4 Participants |
| Region of Enrollment Chile | 7 Participants | 11 Participants | 4 Participants |
| Region of Enrollment China | 6 Participants | 9 Participants | 3 Participants |
| Region of Enrollment Colombia | 2 Participants | 3 Participants | 1 Participants |
| Region of Enrollment Czech Republic | 38 Participants | 69 Participants | 31 Participants |
| Region of Enrollment Denmark | 5 Participants | 6 Participants | 1 Participants |
| Region of Enrollment France | 6 Participants | 16 Participants | 10 Participants |
| Region of Enrollment Germany | 6 Participants | 11 Participants | 5 Participants |
| Region of Enrollment Greece | 63 Participants | 113 Participants | 50 Participants |
| Region of Enrollment Hungary | 7 Participants | 12 Participants | 5 Participants |
| Region of Enrollment Israel | 11 Participants | 16 Participants | 5 Participants |
| Region of Enrollment Italy | 34 Participants | 52 Participants | 18 Participants |
| Region of Enrollment Japan | 17 Participants | 32 Participants | 15 Participants |
| Region of Enrollment Korea, Republic Of | 17 Participants | 27 Participants | 10 Participants |
| Region of Enrollment Mexico | 4 Participants | 6 Participants | 2 Participants |
| Region of Enrollment Poland | 13 Participants | 15 Participants | 2 Participants |
| Region of Enrollment Portugal | 10 Participants | 16 Participants | 6 Participants |
| Region of Enrollment Russia | 6 Participants | 8 Participants | 2 Participants |
| Region of Enrollment Serbia | 13 Participants | 24 Participants | 11 Participants |
| Region of Enrollment Singapore | 8 Participants | 12 Participants | 4 Participants |
| Region of Enrollment South Africa | 5 Participants | 7 Participants | 2 Participants |
| Region of Enrollment Spain | 25 Participants | 48 Participants | 23 Participants |
| Region of Enrollment Sweden | 3 Participants | 6 Participants | 3 Participants |
| Region of Enrollment Switzerland | 1 Participants | 2 Participants | 1 Participants |
| Region of Enrollment Taiwan, Province Of China | 5 Participants | 8 Participants | 3 Participants |
| Region of Enrollment Thailand | 8 Participants | 10 Participants | 2 Participants |
| Region of Enrollment Turkey | 8 Participants | 12 Participants | 4 Participants |
| Region of Enrollment United Kingdom | 46 Participants | 66 Participants | 20 Participants |
| Region of Enrollment United States | 6 Participants | 9 Participants | 3 Participants |
| Sex: Female, Male Female | 203 Participants | 329 Participants | 126 Participants |
| Sex: Female, Male Male | 222 Participants | 377 Participants | 155 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 115 / 281 | 184 / 425 |
| other Total, other adverse events | 188 / 276 | 340 / 426 |
| serious Total, serious adverse events | 48 / 276 | 101 / 426 |
Outcome results
Primary
Progression Free Survival (PFS)
PFS is defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause, as evaluated by an independent review committee (IRC) according to International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurs first. Per IMWG criteria, PD is defined as, increase of 25% of lowest response value in one or more of following criteria: serum M-component (absolute increase ≥0.5 g/ deciliter (dL)); or urine M-component (absolute increase ≥200 mg/24-hour); difference between involved and uninvolved free light chains (FLC) levels (absolute increase \>10 mg/dL); or bone marrow plasma cell percentage (absolute plasma cell percentage ≥10%); development of new/ increase in size of existing bone lesions or soft tissue plasmacytoma; or development of hypercalcemia (corrected serum calcium \>11.5mg/dL).
Time frame: From randomization until PD or death (up to 52 months)
Population: ITT Population included all participants who were randomized and had post-randomization data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Progression Free Survival (PFS) | 9.4 months |
| Ixazomib | Progression Free Survival (PFS) | 17.4 months |
Secondary
Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status
ECOG performance status assesses a participant's performance status on a 6-point scale ranging from 0=fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (\>50% of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited self-care, confined to bed/chair \>50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5=dead. Lower grades indicate improvement.
Time frame: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26, progression free survival follow-up (PFSFU)- Visit 37 and progressive disease follow-up (PDFU)- Visit 26 (cycle length=28 days)
Population: Safety Population included all participants who received at least 1 dose of ixazomib or placebo. Three placebo participants who erroneously received a single dose of ixazomib were included in the ixazomib arm of the safety population. Overall number of participants analyzed is the number of participants with data available for analyses. Number analyzed is the number of participants with data available for analyses for the specified category.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 15 Day 1 | -0.0 score on a scale | Standard Deviation 0.53 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 3 Day 1 | -0.0 score on a scale | Standard Deviation 0.36 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 16 Day 1 | -0.0 score on a scale | Standard Deviation 0.51 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 8 Day 1 | -0.1 score on a scale | Standard Deviation 0.48 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 17 Day 1 | -0.0 score on a scale | Standard Deviation 0.54 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 18 Day 1 | 0.0 score on a scale | Standard Deviation 0.51 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 9 Day 1 | -0.1 score on a scale | Standard Deviation 0.47 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 19 Day 1 | 0.0 score on a scale | Standard Deviation 0.47 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 10 Day 1 | -0.1 score on a scale | Standard Deviation 0.52 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 20 Day 1 | 0.0 score on a scale | Standard Deviation 0.46 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 4 Day 1 | -0.0 score on a scale | Standard Deviation 0.39 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 21 Day 1 | 0.0 score on a scale | Standard Deviation 0.48 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 11 Day 1 | -0.1 score on a scale | Standard Deviation 0.51 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 22 Day 1 | 0.1 score on a scale | Standard Deviation 0.51 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 2 Day 1 | -0.0 score on a scale | Standard Deviation 0.36 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 23 Day 1 | 0.0 score on a scale | Standard Deviation 0.44 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 12 Day 1 | -0.1 score on a scale | Standard Deviation 0.56 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 24 Day 1 | 0.1 score on a scale | Standard Deviation 0.54 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 5 Day 1 | -0.0 score on a scale | Standard Deviation 0.44 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 25 Day 1 | 0.0 score on a scale | Standard Deviation 0.42 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 13 Day 1 | -0.0 score on a scale | Standard Deviation 0.54 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 26 Day 1 | 0.0 score on a scale | Standard Deviation 0.47 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 14 Day 1 | 0.0 score on a scale | Standard Deviation 0.53 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 7 Day 1 | -0.0 score on a scale | Standard Deviation 0.49 |
| Placebo | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 6 Day 1 | -0.0 score on a scale | Standard Deviation 0.46 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 26 Day 1 | -0.0 score on a scale | Standard Deviation 0.47 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | PFSFU- Visit 37 | 1.0 score on a scale | — |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | PDFU- Visit 26 | 1.0 score on a scale | — |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 6 Day 1 | -0.0 score on a scale | Standard Deviation 0.43 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 9 Day 1 | -0.0 score on a scale | Standard Deviation 0.45 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 2 Day 1 | -0.0 score on a scale | Standard Deviation 0.42 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 3 Day 1 | -0.0 score on a scale | Standard Deviation 0.42 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 4 Day 1 | -0.1 score on a scale | Standard Deviation 0.42 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 5 Day 1 | -0.0 score on a scale | Standard Deviation 0.44 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 7 Day 1 | -0.0 score on a scale | Standard Deviation 0.42 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 8 Day 1 | -0.0 score on a scale | Standard Deviation 0.42 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 10 Day 1 | -0.0 score on a scale | Standard Deviation 0.47 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 11 Day 1 | -0.0 score on a scale | Standard Deviation 0.43 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 12 Day 1 | -0.0 score on a scale | Standard Deviation 0.43 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 13 Day 1 | -0.0 score on a scale | Standard Deviation 0.46 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 14 Day 1 | -0.0 score on a scale | Standard Deviation 0.44 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 15 Day 1 | -0.0 score on a scale | Standard Deviation 0.49 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 16 Day 1 | -0.0 score on a scale | Standard Deviation 0.49 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 17 Day 1 | -0.0 score on a scale | Standard Deviation 0.5 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 18 Day 1 | -0.0 score on a scale | Standard Deviation 0.51 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 19 Day 1 | -0.0 score on a scale | Standard Deviation 0.49 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 20 Day 1 | -0.0 score on a scale | Standard Deviation 0.49 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 21 Day 1 | -0.0 score on a scale | Standard Deviation 0.52 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 22 Day 1 | -0.0 score on a scale | Standard Deviation 0.52 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 23 Day 1 | -0.0 score on a scale | Standard Deviation 0.48 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 24 Day 1 | -0.0 score on a scale | Standard Deviation 0.47 |
| Ixazomib | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Cycle 25 Day 1 | -0.0 score on a scale | Standard Deviation 0.47 |
Secondary
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS)
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The change from baseline in GHS (EORTC QLQ-C30) score is presented. Participant responses to the question How would you rate your overall health during the past week? are scored on a 7-point scale (1=very poor to 7=excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall GHS.
Time frame: Baseline, Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26 (cycle length=28 days)
Population: ITT Population included all participants who were randomized and had post-randomization data. Overall number analyzed is the number of participants with data available for analyses. Number analyzed is the number of participants with data available for analyses for the specified time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 20 | 1.1 score on a scale | Standard Deviation 17.95 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 13 | 4.2 score on a scale | Standard Deviation 16.13 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 6 | 1.0 score on a scale | Standard Deviation 18.33 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 14 | 3.1 score on a scale | Standard Deviation 16.99 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 2 | 1.7 score on a scale | Standard Deviation 16.63 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 15 | 2.2 score on a scale | Standard Deviation 16.74 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 7 | 3.1 score on a scale | Standard Deviation 16.32 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 16 | 2.5 score on a scale | Standard Deviation 15.57 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 8 | 0.9 score on a scale | Standard Deviation 18.07 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 17 | 2.4 score on a scale | Standard Deviation 15.09 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 3 | 2.1 score on a scale | Standard Deviation 15.74 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 18 | 0.5 score on a scale | Standard Deviation 18.4 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 9 | 1.4 score on a scale | Standard Deviation 16.67 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 19 | 1.6 score on a scale | Standard Deviation 18.07 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 4 | 1.5 score on a scale | Standard Deviation 16.8 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 21 | 1.5 score on a scale | Standard Deviation 16.39 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 10 | 2.0 score on a scale | Standard Deviation 16.38 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 22 | 1.6 score on a scale | Standard Deviation 15.55 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 23 | 2.1 score on a scale | Standard Deviation 19.01 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 11 | 3.9 score on a scale | Standard Deviation 17.37 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 24 | -0.3 score on a scale | Standard Deviation 20.46 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 5 | 1.8 score on a scale | Standard Deviation 15.79 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 25 | 0.0 score on a scale | Standard Deviation 18.8 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 12 | 3.9 score on a scale | Standard Deviation 14.53 |
| Placebo | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 26 | 2.8 score on a scale | Standard Deviation 17.49 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 22 | 1.0 score on a scale | Standard Deviation 17.13 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 7 | -0.7 score on a scale | Standard Deviation 17.28 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 20 | 0.4 score on a scale | Standard Deviation 16.13 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 26 | 0.9 score on a scale | Standard Deviation 17.26 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 3 | -1.2 score on a scale | Standard Deviation 17.14 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 4 | -0.6 score on a scale | Standard Deviation 16.53 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 5 | 0.6 score on a scale | Standard Deviation 16.33 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 6 | -1.5 score on a scale | Standard Deviation 16.56 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 8 | -0.4 score on a scale | Standard Deviation 17.44 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 9 | 0.1 score on a scale | Standard Deviation 16.57 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 10 | -1.6 score on a scale | Standard Deviation 17.82 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 11 | 0.2 score on a scale | Standard Deviation 17.75 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 12 | 0.3 score on a scale | Standard Deviation 16.26 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 13 | -0.5 score on a scale | Standard Deviation 16.85 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 14 | -1.1 score on a scale | Standard Deviation 17.45 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 15 | -0.7 score on a scale | Standard Deviation 17.65 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 16 | 0.5 score on a scale | Standard Deviation 17.03 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 17 | -0.2 score on a scale | Standard Deviation 18.09 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 18 | 1.7 score on a scale | Standard Deviation 16.87 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 19 | 1.1 score on a scale | Standard Deviation 17.24 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 21 | 1.3 score on a scale | Standard Deviation 16.19 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 2 | -0.1 score on a scale | Standard Deviation 16.77 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 23 | 0.9 score on a scale | Standard Deviation 16.96 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 24 | 2.3 score on a scale | Standard Deviation 15.65 |
| Ixazomib | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) | Cycle 25 | 0.3 score on a scale | Standard Deviation 17.52 |
Secondary
Correlation Between Frailty Status and PFS and OS
Participant's frailty status is classified as fit, unfit or frail on the bases of 4 components: age, the Charlson comorbidity scoring system without age weighting, the Katz index of independence in activities of daily living, and the Lawton instrumental activities of daily living scale. The sum of the 4 frailty scores equals the total frailty score. A total frailty score of 0 corresponds to a frailty status of fit; a total score of 1, to unfit; and a total score of 2 or more, to frail. PFS is defined as the time from the date of randomization to the date of first documentation of PD or death from any cause, as evaluated by an IRC according to IMWG criteria, or death due to any cause, whichever occurs first, assessed for up to 52 months in this outcome measure. OS will be measured as the time from the date of randomization to the date of death, assessed for up to 52 months in this outcome measure.
Time frame: From randomization up to 52 months
Population: ITT Population included all participants who were randomized and had post-randomization data. Overall number analyzed is the number of participants with data available for analyses. Number analyzed is the number of participants with data available for analysis for the specified category.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Placebo | Correlation Between Frailty Status and PFS and OS | PFS Based on Frailty Status of Fit | 8.5 months |
| Placebo | Correlation Between Frailty Status and PFS and OS | PFS Based on Frailty Status of Unfit | 10.6 months |
| Placebo | Correlation Between Frailty Status and PFS and OS | PFS Based on Frailty Status of Frail | 11.1 months |
| Placebo | Correlation Between Frailty Status and PFS and OS | OS Based on Frailty Status of Fit | NA months |
| Placebo | Correlation Between Frailty Status and PFS and OS | OS Based on Frailty Status of Unfit | NA months |
| Placebo | Correlation Between Frailty Status and PFS and OS | OS Based on Frailty Status of Frail | 42.5 months |
| Ixazomib | Correlation Between Frailty Status and PFS and OS | OS Based on Frailty Status of Unfit | NA months |
| Ixazomib | Correlation Between Frailty Status and PFS and OS | PFS Based on Frailty Status of Fit | 18.6 months |
| Ixazomib | Correlation Between Frailty Status and PFS and OS | OS Based on Frailty Status of Fit | NA months |
| Ixazomib | Correlation Between Frailty Status and PFS and OS | PFS Based on Frailty Status of Unfit | 17.6 months |
| Ixazomib | Correlation Between Frailty Status and PFS and OS | OS Based on Frailty Status of Frail | 46.5 months |
| Ixazomib | Correlation Between Frailty Status and PFS and OS | PFS Based on Frailty Status of Frail | 15.4 months |
Comparison: PFS Based on Frailty Status of Fitp-value: <0.00195% CI: [0.387, 0.727]Log Rank
Comparison: PFS Based on Frailty Status of Unfitp-value: =0.09895% CI: [0.526, 1.058]Log Rank
Comparison: PFS Based on Frailty Status of Frailp-value: =0.14795% CI: [0.481, 1.117]Log Rank
Comparison: OS Based on Frailty Status of Fitp-value: =0.71495% CI: [0.502, 1.602]Log Rank
Comparison: OS Based on Frailty Status of Unfitp-value: =0.12495% CI: [0.85, 3.601]Log Rank
Comparison: OS Based on Frailty Status of Frailp-value: =0.6395% CI: [0.448, 1.627]Log Rank
Secondary
Correlation of MRD Status With PFS and OS
PFS is defined as the time from the date of randomization to the date of first documentation of PD or death from any cause, as evaluated by an IRC according to IMWG criteria, or death due to any cause, whichever occurred first, assessed for up to 52 months in this outcome measure. OS was measured as the time from the date of randomization to the date of death, assessed for up to 52 months in this outcome measure. Participants with various types of known MRD status were pooled together for analysis of overall survival in this outcome measure.
Time frame: From randomization up to 52 months
Population: ITT Population included all participants who were randomized and had post-randomization data. Overall number analyzed is the number of participants with data available for analyses. Number analyzed is the number of participants with data available for analyses for the specified category.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Placebo | Correlation of MRD Status With PFS and OS | PFS for Participants with Known MRD+ at Study Entry | 9.3 months |
| Placebo | Correlation of MRD Status With PFS and OS | PFS for Participants with Known MRD- at Study Entry | NA months |
| Placebo | Correlation of MRD Status With PFS and OS | OS for Participants with Known MRD Status (MRD- Status, MRD+ Status) at Study Entry | NA months |
| Ixazomib | Correlation of MRD Status With PFS and OS | PFS for Participants with Known MRD+ at Study Entry | 16.9 months |
| Ixazomib | Correlation of MRD Status With PFS and OS | PFS for Participants with Known MRD- at Study Entry | 40.5 months |
| Ixazomib | Correlation of MRD Status With PFS and OS | OS for Participants with Known MRD Status (MRD- Status, MRD+ Status) at Study Entry | NA months |
Comparison: PFS for Participants with Known MRD+ at Study Entryp-value: =0.00195% CI: [0.425, 0.796]Log Rank
Comparison: PFS for Participants with Known MRD- at Study Entryp-value: =0.39895% CI: [0.563, 4.194]Log Rank
Comparison: OS for Participants with Known MRD Status (MRD- Status, MRD+ Status) at Study Entryp-value: =0.01295% CI: [1.194, 86.649]Log Rank
Secondary
Duration of Next-line Therapy
Duration of next-line therapy is defined as the time from the date of the first dose of the next line of antineoplastic therapy coming after study treatment to the date of the last dose.
Time frame: From randomization until PD or death (up to 52 months)
Population: ITT Population included all participants who were randomized and had post-randomization data. Overall number analyzed is the number of participants with data available for analyses.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Duration of Next-line Therapy | 14.0 months |
| Ixazomib | Duration of Next-line Therapy | 8.7 months |
95% CI: [0.968, 1.727]
Secondary
OS in a High-risk Population
High-risk population included but not be limited to participants carrying cytogenetic deletion (del)17, translocation \[t\](4;14), t(14;16). OS was measured as the time from the date of randomization to the date of death.
Time frame: From the date of randomization and every 12 weeks after PD on next-line therapy until death (up to 88 months)
Population: ITT Population included all participants who were randomized and had post-randomization data. Overall number of participants analyzed is the number of participants present in the high-risk group.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | OS in a High-risk Population | 48.3 months |
| Ixazomib | OS in a High-risk Population | 37.3 months |
Secondary
Overall Survival (OS)
OS was measured as the time from the date of randomization to the date of death.
Time frame: From the date of randomization and every 12 weeks after PD on next-line therapy until death (up to 88 months)
Population: ITT Population included all participants who were randomized and had post-randomization data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Overall Survival (OS) | 69.5 months |
| Ixazomib | Overall Survival (OS) | 64.8 months |
p-value: =0.47395% CI: [0.861, 1.381]Log Rank
Secondary
Percentage of Participants Who Achieve or Maintain Any Best Response Category During the Treatment Period
Response was assessed according to IMWG criteria based on IRC assessment. Best response included PR, VGPR and CR. PR= \>=50% reduction of serum M protein and \>=90% or \<200 mg reduction urinary M protein in 24-hour, or \>50% decrease in difference between involved and uninvolved FLC levels, or \>50% reduction in bone marrow plasma cells, if bone marrow plasma cells \>30% and \>50% reduction in size of soft tissue plasmacytomas at baseline. VGPR= \>90% reduction (\<100 mg/24-hour) in serum M-protein + urine M-protein detectable by immunofixation but not on electrophoresis. Complete response= \>5% plasma cells in myelogram with absence of paraprotein in serum and urine according to immunofixation.
Time frame: Up to 27 months
Population: ITT Population included all participants who were randomized and had post-randomization data. The percentages are rounded off to the single nearest decimal point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Percentage of Participants Who Achieve or Maintain Any Best Response Category During the Treatment Period | VGPR | 37 percentage of participants |
| Placebo | Percentage of Participants Who Achieve or Maintain Any Best Response Category During the Treatment Period | CR | 28 percentage of participants |
| Placebo | Percentage of Participants Who Achieve or Maintain Any Best Response Category During the Treatment Period | PR | 29 percentage of participants |
| Ixazomib | Percentage of Participants Who Achieve or Maintain Any Best Response Category During the Treatment Period | PR | 25 percentage of participants |
| Ixazomib | Percentage of Participants Who Achieve or Maintain Any Best Response Category During the Treatment Period | VGPR | 34 percentage of participants |
| Ixazomib | Percentage of Participants Who Achieve or Maintain Any Best Response Category During the Treatment Period | CR | 31 percentage of participants |
Secondary
Percentage of Participants Who Develop a New Primary Malignancy
Time frame: From randomization until PD or death (up to 52 months)
Population: Safety Population included all participants who received at least 1 dose of ixazomib or placebo. Three placebo participants who erroneously received a single dose of ixazomib were included in the ixazomib arm of the safety population. The percentages are rounded off to the single nearest decimal point.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants Who Develop a New Primary Malignancy | 6.2 percentage of participants |
| Ixazomib | Percentage of Participants Who Develop a New Primary Malignancy | 5.2 percentage of participants |
Secondary
Percentage of Participants With Conversion From Minimal Residual Disease (MRD) Positive to MRD Negative
Bone marrow aspirates and blood samples were sent to a central laboratory and were assessed for MRD using flow cytometry. MRD negativity was defined as absence of MRD and MRD positivity was defined as presence of MRD. MRD was assessed by 8-color flow cytometry with the IMWG recommended sensitivity of 10\^-5.
Time frame: Up to 52 months
Population: ITT Population included all participants who were randomized and had post-randomization data. Overall number analyzed is the number of participants with data available for analyses. The percentages are rounded off to the nearest single decimal point.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Conversion From Minimal Residual Disease (MRD) Positive to MRD Negative | 3 percentage of participants |
| Ixazomib | Percentage of Participants With Conversion From Minimal Residual Disease (MRD) Positive to MRD Negative | 6 percentage of participants |
Secondary
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAEs were defined as events that occurred after administration of the first dose of ixazomib or placebo through 30 days after the last dose of ixazomib or placebo. A SAE means any untoward medical occurrence that resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was considered medically significant.
Time frame: First dose of study drug through 30 days after last dose of study drug (up to 88 months)
Population: Safety Population included all participants who received at least 1 dose of ixazomib or placebo. Three placebo participants who erroneously received a single dose of ixazomib were included in the ixazomib arm of the safety population. The percentages were rounded off to the nearest single decimal point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAE | 17 percentage of participants |
| Placebo | Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAE | 82 percentage of participants |
| Ixazomib | Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAE | 24 percentage of participants |
| Ixazomib | Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | TEAE | 92 percentage of participants |
Secondary
PFS in a High-risk Population
High-risk population included but not be limited to participants carrying del17, t(4;14), t(14;16). PFS was defined as the time from the date of randomization to the date of first documentation of PD or death from any cause.
Time frame: From randomization until PD or death (up to 52 months)
Population: ITT Population included all participants who were randomized and had post-randomization data. Overall number of participants analyzed is the number of participants present in the high-risk group.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | PFS in a High-risk Population | 9.6 months |
| Ixazomib | PFS in a High-risk Population | 10.1 months |
p-value: =0.96395% CI: [0.631, 1.621]Log Rank
Secondary
Pharmacokinetic Parameter: Plasma Concentration of Ixazomib
Plasma concentrations of the complete hydrolysis product of ixazomib citrate (ixazomib) were measured using a validated liquid chromatography-tandem mass spectrometry (LC/MS/MS) assay.
Time frame: Cycle 1 (1 and 4 hours post-dose Day 1, Days 8 and 15 pre-dose); Cycle 2 and 5 (Days 1 and 8 pre-dose) and Cycles 3, 4, 6 to 10 (Day 1 pre-dose) (cycle length=28 days)
Population: Pharmacokinetic Analysis Population included all participants with at least one pharmacokinetic (PK) sample that was collected and analyzed. Number analyzed is the number of participants with data available for analysis at the specified time point.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 1 Day 1 - 4 Hours Post-dose | 12.698 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 67.835 |
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 1 Day 8 - Pre-dose | 1.683 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 162.3947 |
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 1 Day 1 - 1 Hour Post-dose | 19.353 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 89.2568 |
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 1 Day 15 - Pre-dose | 2.828 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 86.7699 |
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 2 Day 1 - Pre-dose | 1.958 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 170.8938 |
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 2 Day 8 - Pre-dose | 3.217 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 188.6379 |
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 3 Day 1 - Pre-dose | 2.252 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 56.2869 |
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 4 Day 1 - Pre-dose | 2.363 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 52.9781 |
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 5 Day 1 - Pre-dose | 2.328 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 53.0909 |
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 5 Day 8 - Pre-dose | 4.547 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 224.4312 |
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 6 Day 1 - Pre-dose | 2.503 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 52.9349 |
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 7 Day 1 - Pre-dose | 2.585 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 57.9514 |
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 8 Day 1 - Pre-dose | 2.606 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 58.5109 |
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 9 Day 1 - Pre-dose | 2.566 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 58.1094 |
| Placebo | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib | Cycle 10 Day 1 - Pre-dose | 2.686 nanogram per milliliter (ng/mL) | Geometric Coefficient of Variation 50.2494 |
Secondary
Progression Free Survival 2 (PFS2)
PFS2 is defined as the time from the date of randomization to objective PD on next-line treatment using IMWG criteria, or death due to any cause, whichever occurred first.
Time frame: From the date of randomization to every 12 weeks until second PD or death (up to 88 months)
Population: ITT Population included all participants who were randomized and had post-randomization data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Progression Free Survival 2 (PFS2) | 50.3 months |
| Ixazomib | Progression Free Survival 2 (PFS2) | 51.3 months |
p-value: =0.89395% CI: [0.777, 1.246]Log Rank
Secondary
Time to End of the Next-line of Therapy After Study Treatment
Time to end of the next line of therapy is defined as the time from the date of randomization to the date of last dose of the next line of antineoplastic therapy following study treatment.
Time frame: From randomization until PD or death (up to 52 months)
Population: ITT Population included all participants who were randomized and had post-randomization data. Overall number analyzed is the number of participants with data available for analyses.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to End of the Next-line of Therapy After Study Treatment | 25.6 months |
| Ixazomib | Time to End of the Next-line of Therapy After Study Treatment | 23.1 months |
p-value: =0.46295% CI: [0.839, 1.47]Log Rank
Secondary
Time to Improvement of PN Events
PN is defined as the event in the high-level term of peripheral neuropathies NEC according to the MedDRA. A PN event was considered as resolved if its final outcome was resolved with no subsequent PN event of the same preferred term occurring on the improvement date or the day before and after. Time to improvement was defined as the time from the initial onset date (inclusive) to the improvement of event.
Time frame: Up to 52 months
Population: Safety Population included all participants who received at least 1 dose of ixazomib or placebo. Overall number of participants analyzed are the number of participants with events.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to Improvement of PN Events | 81.0 days |
| Ixazomib | Time to Improvement of PN Events | 64.0 days |
Secondary
Time to Next Line Therapy (TTNT)
TTNT is defined as the time from the date of randomization to the date of the first dose of next-line antineoplastic therapy.
Time frame: From randomization until PD or death (up to 52 months)
Population: ITT Population included all participants who were randomized and had post-randomization data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to Next Line Therapy (TTNT) | 16.1 months |
| Ixazomib | Time to Next Line Therapy (TTNT) | 22.1 months |
p-value: =0.01895% CI: [0.631, 0.957]Log Rank
Secondary
Time to Progression (TTP)
TTP is defined as the time from the date of randomization to the date of first documentation of PD, using IMWG criteria.
Time frame: From randomization until PD or death (up to 52 months)
Population: ITT Population included all participants who were randomized and had post-randomization data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to Progression (TTP) | 9.6 months |
| Ixazomib | Time to Progression (TTP) | 17.8 months |
p-value: <0.00195% CI: [0.537, 0.799]Log Rank
Secondary
Time to Resolution of Peripheral Neuropathy (PN) Events
PN is defined as the event in the high-level term of peripheral neuropathies not elsewhere classified (NEC) according to the medical dictionary for regulatory activities (MedDRA). A PN event was considered as resolved if its final outcome was resolved with no subsequent PN event of the same preferred term occurring on the resolution date or the day before and after. Time to resolution was defined as the time from the initial onset date (inclusive) to the resolution date for resolved events.
Time frame: Up to 52 months
Population: Safety Population included all participants who received at least 1 dose of ixazomib or placebo. Overall number of participants analyzed are the number of participants with events.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to Resolution of Peripheral Neuropathy (PN) Events | 196.0 days |
| Ixazomib | Time to Resolution of Peripheral Neuropathy (PN) Events | 451.0 days |